

Cite this: *RSC Chem. Biol.*, 2025, 6, 1616

Characterization of nuclease stability and poly(A)-binding protein binding activity of chemically modified poly(A) tail for *in vivo* applications

Atsushi Hashimoto,^a Yuma Kunitomo,^a Ittoku Kikuchi,^a Hiroki Yamada,^a Keiko Kobayashi,^a Kazuhiro Soshiroda,^a Hiromi Aman,^a Yasuaki Kimura,^d Junichiro Yamamoto,^a Yasuhisa Shiraishi,^a Satoshi Uchida,^{*bc} Hiroshi Abe^{*defg} and Hiroto Iwai^{*a}

The poly(A) tail plays a crucial role in mRNA stability and translation efficiency. Chemical modification of the poly(A) tail is a promising approach for stabilizing mRNA against deadenylation. In this study, we investigated the effect of poly(A) chemical modifications using phosphorothioate (PS), 2'-fluoro (2'-F), 2'-O-methyl (2'-OMe), and 2'-O-methoxyethyl (2'-MOE) modifications. Notably, PS, 2'-OMe, and 2'-MOE modifications conferred resistance to CAF1, an enzyme responsible for deadenylation. Interestingly, only the PS modification retained the poly(A)-binding protein (PABP) binding activity, which is critical for translation, whereas 2'-F, 2'-OMe, and 2'-MOE modifications abolished this activity. Beyond the PS modification, the combination of 2'-F, 2'-OMe, and 2'-MOE modifications resulted in enhanced resistance to both CAF1 and other nucleases. Based on these results, a 12-nucleotide unmodified poly(A) sequence was inserted upstream of the modified poly(A) to confer both nuclease resistance and PABP-binding activity. Notably, the resulting poly(A) formulation significantly prolonged protein expression in cultured cells and mouse skin when applied to epidermal growth factor-encoding therapeutic mRNA. Collectively, this study presents a design concept for poly(A) chemical modifications to achieve durable protein expression from mRNA, offering a promising strategy for enhancing the function of mRNA-based therapeutics.

Received 30th May 2025,
Accepted 17th August 2025

DOI: 10.1039/d5cb00137d

rsc.li/rsc-chembio

Introduction

Despite the successful clinical application of mRNA vaccines and therapeutics, their transient protein expression profile hinders their widespread use.^{1,2} For instance, mRNA-based protein replacement therapy requires repeated administration,

highlighting the need for strategies that prolong protein expression.^{3,4} Engineering the poly(A) tail is a promising solution.^{5,6} The poly(A) tail is a critical mRNA element that contributes significantly to mRNA stability, translation efficiency, and overall gene expression regulation in eukaryotic cells.⁶⁻⁹ The poly(A) tail is added to the 3'-end of the mRNA during posttranscriptional processing and covered by poly(A)-binding protein (PABP).¹⁰⁻¹² These interactions facilitate the formation of a closed-loop structure mediated by the interaction between the 5'-cap structure and poly(A) tail.^{13,14} This closed-loop structure plays an important role in protecting mRNA from exonucleolytic degradation and facilitates the recruitment of ribosomes for translation initiation.^{15,16}

Recent advancements in transcriptome analysis and RNA engineering have revealed that stabilization of the poly(A) tail is a promising approach for increasing mRNA durability.^{5,6,17} Chemical modifications of RNA provide a robust tool for enhancing its enzymatic and physiological stability, as demonstrated by the development of oligonucleotide therapeutics.^{18,19} Although RNA modifications in the 2'-position have been

^a Innovation Center, Research Division, Kyowa Kirin Co., Ltd. 3-6-6 Asahi, Machida, Tokyo, 194-8533, Japan. E-mail: hiroto.iwai.sk@kyowakirin.com

^b Department of Advanced Nanomedical Engineering, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

^c Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki, Japan

^d Department of Chemistry, Graduate School of Science, Nagoya University, Furo, Chikusa, Nagoya 464-8602, Japan

^e Research Center for Materials Science, Nagoya University, Furo, Chikusa, Nagoya 464-8602, Japan

^f CREST, Japan Science and Technology Agency, 7, Gobancho, Chiyoda-ku, Tokyo 102-0076, Japan

^g Institute for Glyco-core Research (iGCORE), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8601, Japan



Table 1 Kinetics parameters obtained *via* SPR analysis of PABP-poly(A) interaction

Name	Length (nt)	Modification	k_a ($M^{-1} s^{-1}$)	k_d (s^{-1})	K_D (M)
Biotin-RNA1	24	—	$2.3 \pm 0.2 \times 10^7$	$3.9 \pm 0.4 \times 10^{-4}$	$1.7 \pm 0.1 \times 10^{-11}$
Biotin-RNA2	24	PS	$3.2 \pm 0.1 \times 10^7$	$2.8 \pm 0.1 \times 10^{-4}$	$9.2 \pm 0.7 \times 10^{-12}$
Biotin-RNA3	24	DNA	n.b.	n.b.	n.b.
Biotin-RNA4	24	2'-OMe	n.b.	n.b.	n.b.
Biotin-RNA5	24	2'-MOE	n.b.	n.b.	n.b.
Biotin-RNA6	24	2'-F	n.b.	n.b.	n.b.
Biotin-RNA7	50	—	$1.6 \pm 0.1 \times 10^7$	$2.3 \pm 0.1 \times 10^{-4}$	$1.5 \pm 0.2 \times 10^{-11}$
Biotin-RNA8	50	U	n.b.	n.b.	n.b.
Biotin-RNA9	50	2'-F, 2'-OMe, 2'-MOE	$3.0 \pm 0.4 \times 10^7$	$1.5 \pm 0.1 \times 10^{-2}$	$5.0 \pm 0.4 \times 10^{-10}$
Biotin-RNA10	12	—	n.d.	n.d.	$1.5 \pm 0.1 \times 10^{-7}$

Each experiment was repeated using biological triplicates and the mean values are listed. The binding affinity of biotin-RNA10 was determined using a steady-state affinity 1 : 1 binding model because the sensorgram was box-shaped. n.b.: no binding, n.d.: not determined.




Fig. 4 *In vitro* stability of highly chemically modified RNA fragments. (A) Design of RNA fragments with chemical modifications. (B) TBE-urea gel image of RNA fragments after CAF1 treatment. Experiments were performed using biological triplicates and representative data are shown. (C) TBE-urea gel image of RNA fragments after treatment of mouse skin lysates. Experiments were performed using biological triplicates and representative data are shown. (D) Time course of the remaining RNA ratio after incubation with CAF1. Data are presented as the mean. (E) Time course of the remaining RNA ratio after incubation with mouse skin lysates. Data are presented as the mean.

Furthermore, to gain a deeper understanding of the individual contributions of these modifications, we prepared control RNA species containing only one of the three tested modifications: fluoro-RNA10 for 2'-MOE, fluoro-RNA11 for 2'-F, and fluoro-RNA12 for 2'-OMe. In the CAF1 assay, F/OMe/MOE

modifications imparted mRNAs with high stability, exhibiting undetectable degradation, even after 1 week of incubation (fluoro-RNA9; Fig. 4B and D). Notably, the 3-nt 2'-MOE modification at the 3'-end completely blocked CAF1 degradation even without upstream 2'-F and 2'-OMe modifications (Fig. 4B and D). This result indicated that the 3'-end 2'-MOE modification of poly(A) is sufficient to inhibit deadenylation, consistent with the findings of previous studies.²⁵ Concurring with the results in Fig. 1, 2'-F modifications alone did not increase the resistance to CAF1 (fluoro-RNA11; Fig. 4B and D). 2'-OMe modifications resulted in the degradation of the unmodified four bases at the 3'-end, leaving the upstream modified sequence intact (fluoro-RNA12; Fig. 4B and D). This result supported the findings in Fig. 1, showing the high stability against CAF1 resulting from the 2'-OMe modification.

mRNA is degraded not only by CAF1 but also by other nucleases.³⁵ To evaluate the overall stability against various nucleases, we assessed the stability of the poly(A) tail in mouse skin lysates. We used mouse skin lysates because the subsequent *in vivo* studies were performed using mouse skin samples. After incubating 5'-fluorescently labeled RNA substrates with diluted skin lysates, we subjected the reaction mixtures to denaturing polyacrylamide gel electrophoresis. Importantly, the experimental groups differed only in the composition of modified adenosine residues. Therefore, any differences observed between groups can be attributed to the effects of the specific modification compositions. We first compared poly(A) with poly(U) and found that poly(U) degraded faster than poly(A) (Fig. S1). This result aligned with previous studies indicating that ribonuclease activity on the mouse skin surface is pyrimidine selective.³⁶ We then assessed the chemically modified poly(A) tails and found that F/OMe/MOE modifications resulted in highly stable mRNAs in mouse skin lysates (fluoro-RNA9; Fig. 4C and E). Upon studying the contribution of each modification separately, we noted that 2'-F modifications (fluoro-RNA11) but not 2'-OMe or terminal 2'-MOE modifications (fluoro-RNA10 and 12) increased nuclease stability compared with unmodified poly(A) (fluoro-RNA8) (Fig. 4C and E).

Interestingly, we observed that each modification exhibited different preferences for preventing degradation by specific types of nucleases, with 2'-OMe and 2'-MOE modifications



Although the chemical synthesis of long RNA strands is challenging, the splint ligation of short RNA fragments helps avoid this issue. Indeed, we previously reported the chemical synthesis of mRNA with extensive sugar modifications using splint ligation.³³ Additionally, a subsequent chemical capping reaction enables complete chemical synthesis of mRNA.⁴⁶ We synthesized the EGF mRNAs using T4 RNA ligase 2 through convergent splint ligation with the corresponding RNA fragments (Fig. 6A). The details of the synthesis results are described in the SI. Notably, the purified mRNAs were homogeneous in length, showing a single peak on PAGE and capillary gel electrophoresis (Fig. 6B, C and Fig. S6). Splint DNA digestion was confirmed using denaturing PAGE, as previously described³⁴ (Fig. S5).

Poly(A)-modified EGF mRNA showed prolonged translational activity

First, we evaluated the effects of chemical modifications of the poly(A) tail in HeLa cells, a human cell line. After treating HeLa cells with lipid-based carriers loaded with EGF mRNA, we measured EGF protein concentrations in the culture medium. After each measurement, we replaced the medium with fresh medium. Interestingly, the benefit of poly(A) tail modifications became obvious only at a later time point, potentially reflecting their mRNA stabilizing effect (Fig. 7A). Specifically, poly(A)-modified mRNA resulted in the production of a higher concentration of EGF than the unmodified mRNA at 48 h after mRNA addition, but not at 6 and 24 h. At 6 h, poly(A)-modified mRNA resulted in lower EGF levels than unmodified mRNA, possibly

because of the lower affinity of PABP for poly(A)-modified mRNA (Fig. 5).

Next, we explored the *in vivo* delivery of poly(A)-modified mRNA to the skin, as EGF mRNA is a promising candidate for treating skin ulcers. As a delivery method, we selected naked mRNA injection using a needle-free pyro-drive liquid jet injector (PYRO), which facilitates the penetration of mRNA through the cell membrane into skin cells *via* physical pressure.⁵⁰ To confirm the effect of PYRO, naked luciferase mRNA was injected into mice using either a needle and syringe (N&S) or PYRO, followed by luminescence intensity measurements 4 h after injection. We found that PYRO improved luminescence intensity by 11-fold at a dose of 10 μg per head and 16-fold at a dose of 30 μg per head compared with N&S (Fig. S2). These data corroborate previous studies showing the benefits of PYRO for naked mRNA delivery to the skin.⁵⁰

Finally, we assessed the *in vivo* activity of poly(A)-modified EGF mRNA (Fig. 7B). For this purpose, we administered EGF mRNA intradermally using PYRO, followed by continuous measurement of EGF protein concentration in the skin. Although EGF expression levels were comparable between poly(A)-modified and unmodified mRNAs at 4 h postinjection, poly(A)-modified mRNA showed enhanced expression at 96 and 168 h. Strikingly, poly(A)-modified EGF mRNA exhibited extended protein expression for up to 1 week, whereas unmodified mRNA showed no detectable protein expression at that time point (Fig. 7B).

In summary, our data showed that poly(A) tail modifications significantly enhanced protein expression *in vivo*, which is likely due to the enhanced stability of the poly(A)-modified mRNA. Prolonged EGF expression could benefit future applications of EGF mRNA therapeutics in the treatment of skin ulcers. We are planning a future study that will include therapeutic application testing and a comprehensive analysis of the *in vivo* functionality of poly(A)-modified mRNA, including expression kinetics and total protein output.




Fig. 7 *In vitro* and *in vivo* stability of EGF-mRNA with chemical modifications on the poly(A) tail. (A) Time course of EGF protein concentration secreted from HeLa cells. Bars indicate mean values. The tests were performed in biological triplicates. Blue: EGF-mRNA_Unmod, red: EGF-mRNA_Mod. Statistical analysis between the two samples was performed using Šidák multiple comparison test. Untreated and mock wells containing the transfection reagent without mRNAs were prepared as negative controls. The protein levels were either at background level or below the lower limit of quantitation (LLOQ). (B) Relative EGF protein levels in mice skin lysates. The vertical axis shows EGF protein concentration normalized by total protein level on a log scale. The tests were performed in biological quadruplicates. Statistical analysis between the two samples was performed using Šidák multiple comparison test. Dots indicate measurements for each individual mouse and bars indicate mean values. Blue: EGF-mRNA_Unmod, red: EGF-mRNA_Mod. The protein level was at LLOQ in mice treated with citrate-saline buffer (10 mM citrate, 130 mM NaCl pH 7.5) used as negative control.⁵¹ (A) and (B), Statistical differences: n.s., $p > 0.05$; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$. Created in BioRender. Hashimoto, A. (2025) <https://BioRender.com/zc59z6l>.

Experimental

Preparation of recombinant hCAF1 and hPABP

The vectors used to express hCAF1 and hPABP in our study, pET-28a(+)-HIS8/SUMO3/TEV/CAF1 and pCS-6xHis/TEV/hPABPC1 [NM_002568.4] respectively, were constructed and packaged by VectorBuilder Inc. (Chicago, IL, USA). Detailed information about these vectors can be retrieved from <https://www.vectorbuilder.com> using the vector IDs, VB221023-1216mte and VB231222-2539wqp. Proteins were expressed in *E. coli* BL21 (DE3) Star cells (Invitrogen, Thermo Fisher Scientific, Carlsbad, CA, USA). Protein expression was induced with 1 mM IPTG when OD600 reached approximately 0.5. To obtain CAF1, cells were further cultured for approximately 20 h at 22 °C. Cell pellets were lysed with B-PER (Thermo Fisher Scientific, Waltham, MA, USA), and the proteins in the supernatant were purified using the cComplete™ His-Tag Purification Resin (Roche, Basel, Switzerland). Purified proteins were desalted with NAP-25 (Cytiva, Marlborough, MA, USA), and the SUMO tag was cleaved with



TEV protease (Promega, Madison, WI, USA). The remaining SUMO tag was removed using the cOmplete™ His-Tag Purification Resin, followed by purification in a Superdex 200 Increase GL 10/300 column (Cytiva, Marlborough, MA, USA). To obtain PABP, cells were cultured for approximately 20 h at 15 °C after IPTG stimulation. Cell pellets were lysed using B-PER supplemented with 125 U per mL benzonase (Merck & Co., Inc., Rahway, NJ, USA). PABP-bound nucleic acids were digested with benzonase and further removed by 0.1% (v/v) poly (ethyleneimine) treatment (Nacalai, Kyoto, Japan). The proteins were treated with the cOmplete™ His-Tag Purification Resin, followed by purification in a Superdex 200 Increase GL 10/300 column. The His-tag was retained because removal *via* TEV protease digestion followed by purification using the cOmplete™ His-Tag Purification Resin resulted in a substantial decrease in protein yield.

***In vitro* deadenylation assay**

The 5'-end of substrate RNAs was labeled with ATTO488. All fluorescently labeled oligonucleotides were purchased from Gene Design (Osaka, Japan). The stability of CAF1 was assessed as follows: 250 nM RNA fragments were mixed with 2.5 μM CAF1 in a reaction buffer (20 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl₂, and 1 mM DTT pH 8.0) at 37 °C. At each time point, TBE-urea sample buffer (Thermo Fisher Scientific) was added to the reaction mixture to stop the degradation. The reaction products were resolved on 10% Novex TBE-urea gels (Thermo Fisher Scientific). The gel was visualized using an LAS-3000 system (Fujifilm, Tokyo, Japan), and band intensities were measured using the Multi Gauge V3.0 software (Fujifilm). The stability against mouse skin lysates was assessed using the same method. Briefly, 250 nM RNA fragments were mixed with 0.8% mouse skin lysates, and the reaction products were resolved on 15% Novex TBE-urea Gels.

Surface plasmon resonance (SPR)

The SPR binding assay was performed using a Biacore T200 system (GE Healthcare, Chicago, IL, USA). The 5'-biotinylated RNA fragments were captured on a streptavidin-coated sensor chip (GE Healthcare) in running buffer (10 mM HEPES, 600 mM NaCl, 3 mM EDTA, and 0.005% v/v surfactant P20 pH 7.4). A flow cell in which the RNA fragments were not captured was used as a reference cell. All experiments were conducted at 25 °C at a flow rate of 30 μL min⁻¹. To measure PABP binding to A24 and A40, PABP was injected for 2 min and allowed to dissociate for 10 min. For A12, the dissociation time was 3 min. The surface was regenerated using 0.1% SDS for 2 min. The dataset was fitted with a 1 : 1 binding model and the kinetic parameters were determined.

Oligonucleotides

Oligonucleotides used for the *in vitro* deadenylation assay and SPR were purchased from Gene Design. The RNA fragments used for chemical synthesis of mRNAs were purchased from Nippon Shokubai Co., Ltd (Osaka, Japan) and Gene Design. The

DNA fragments were purchased from Gene Design and MilliporeSigma (Burlington, MA, USA).

Evaluation of translational activity of EGF mRNAs in HeLa cells

The translational activity of mRNAs was evaluated in HeLa cells. HeLa cells were cultured in DMEM medium supplemented with 10% FBS at 37 °C and 5% CO₂. HeLa cells were seeded at 1.0 × 10⁴ cells per well and cultured overnight. In the following day, old medium was removed and fresh Opti-MEM medium supplemented with 1% (v/v) BSA was added. mRNAs were mixed with 0.3% Lipofectamine MessengerMAX Transfection Reagent (Thermo Fisher Scientific) and added to HeLa cells. At each time point, the supernatant was collected and fresh Opti-MEM medium supplemented with 1% (v/v) BSA was added. The EGF concentration in the supernatant was evaluated using the AlphaLISA Human EGF immunoassay kit (Revvity, Waltham, MA, USA) according to the manufacturer's protocol. Data processing and statistical analyses were conducted using the GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA).

Mice

All animal studies were conducted under the "Standards for Proper Conduct of Animal Experiments" established by Kyowa Kirin Co., Ltd, and received approval from the company's Institutional Animal Care and Use Committee (approval no: AN00043-Z01-24). Kyowa Kirin Co., Ltd is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Five-week-old male BALB/cA_Jcl mice were purchased from CREA Japan (Tokyo, Japan).

Evaluation of translational activity of EGF mRNAs *in vivo*

The mRNA samples were administered intradermally using a needle syringe or an Actranza[®] lab. i.d. delivery device (Daicel Corporation, Osaka, Japan). The mice were euthanized under anesthesia at 4, 96, and 168 h after administration. Skin samples were harvested, immediately frozen in liquid nitrogen, and homogenized using a ShakeMaster Neo (Bio Medical Science Inc., Tokyo, Japan). The crushed samples were resuspended in D-PBS(-) containing a protease inhibitor. At 4 °C, the samples were centrifuged at 9100 × *g* for 10 min. After centrifugation, the supernatant was collected and designated as the *in vivo* lysate. The concentration of hEGF protein in the lysate was quantified using the AlphaLISA Human EGF Immunoassay Kit (Revvity) according to the manufacturer's instructions. A calibration curve was constructed using Recombinant Human EGF GMP Protein, CF (R&D Systems, Minneapolis, MN, USA) diluted in D-PBS(-).

Delivery of firefly luciferase mRNA *in vivo*

Imaging analysis for the expression of 10 or 30 μg per head CleanCap[®] Fluc mRNA (5moU) (TriLink, San Diego, CA, USA) after a single intradermal administration was performed using the IVIS system (PerkinElmer, Waltham, MA, USA). The mice were imaged 4 h after administration of either N&S or Pyro.



Mice were anesthetized with isoflurane and subcutaneously injected with 3 mg per head VivoGlo™ Luciferin, *In Vivo* Grade (Promega) 15 min before imaging.

Conclusions

This study comprehensively evaluated the effect of chemical modifications on the poly(A) tail of mRNA, particularly at high modification rates. Among them, PS, 2'-OMe, and 2'-MOE modifications dramatically enhanced mRNA stability against CAF1, whereas only PS maintained PABP binding at a modification rate of approximately 50%. Beyond the PS modification, combined modification of the poly(A) tail with 2'-F, 2'-OMe, and 2'-MOE significantly increased mRNA resistance to both CAF1 and nucleases in mouse skin lysates. Although 2'-F, 2'-OMe, and 2'-MOE modifications obstructed PABP binding, a poly(A) tail with this combinational modification regained PABP binding activity after the insertion of a 12-nt unmodified poly(A) upstream of the modified poly(A) sequence, even at a 100% modification rate in the 28-nt poly(A) sequence at the 3'-end. Importantly, the resulting poly(A) formulation significantly prolonged protein translation in cultured cells and mouse skin when applied to EGF mRNA. Although the transient protein expression profile remains a major obstacle to the widespread application of mRNA therapeutics, our findings offer a promising solution to this challenge.

Author contributions

Atsushi Hashimoto: conceptualization, investigation, visualization, writing – original draft. Yuma Kunitomo: investigation, visualization, writing – original draft. Ittoku Kikuchi: investigation, visualization. Hiroki Yamada: investigation, writing – review & editing. Keiko Kobayashi: investigation. Kazuhiro Soshiroda: investigation. Hiromi Aman: investigation. Yasuaki Kimura: writing – review & editing, supervision. Yasuhisa Shiraishi: writing – review & editing, supervision. Satoshi Uchida: writing – review & editing, supervision. Hiroshi Abe: writing – review & editing, supervision. Junichiro Yamamoto: writing – review & editing, project administration, supervision. Hiroto Iwai: conceptualization, writing – review & editing, project administration, supervision.

Conflicts of interest

AH, YK, IK, HY, KK, KS, HA, YS, JY, and HI are employees of Kyowa Kirin Co. Ltd.

Data availability

The data supporting this study are included in the SI. See DOI: <https://doi.org/10.1039/d5cb00137d>

Acknowledgements

This work was funded by Kyowa Kirin Co. Ltd.

Notes and references

- U. Sahin, K. Karikó and Ö. Türeci, *Nat. Rev. Drug Discovery*, 2014, **13**, 759–780.
- Y. Weng, C. Li, T. Yang, B. Hu, M. Zhang, S. Guo, H. Xiao, X. J. Liang and Y. Huang, *Biotechnol. Adv.*, 2020, **40**, 107534.
- E. Rohner, R. Yang, K. S. Foo, A. Goedel and K. R. Chien, *Nat. Biotechnol.*, 2022, **40**, 1586–1600.
- C. Y. Chen, D. M. Tran, A. Cavedon, X. Cai, R. Rajendran, M. J. Lyle, P. G. V. Martini and C. H. Miao, *Mol. Ther. Nucleic Acids*, 2020, **20**, 534–544.
- D. Strzelecka, M. Smietanski, P. J. Sikorski, M. Warminski, J. Kowalska and J. Jemielity, *RNA*, 2020, **26**, 1815–1837.
- A. Aditham, H. Shi, J. Guo, H. Zeng, Y. Zhou, S. D. Wade, J. Huang, J. Liu and X. Wang, *ACS Chem. Biol.*, 2022, **17**, 3352–3366.
- J. Gorski, M. R. Morrison, C. G. Merkel and J. B. Lingrel, *Nature*, 1975, **253**, 749–751.
- A. O. Subtelny, S. W. Eichhorn, G. R. Chen, H. Sive and D. P. Bartel, *Nature*, 2014, **508**, 66–71.
- J. Lim, M. Lee, A. Son, H. Chang and V. N. Kim, *Genes Dev.*, 2016, **30**, 1671–1682.
- J. B. Rodriguez-Molina and M. Turtola, *FEBS Open Bio*, 2023, **13**, 1140–1153.
- R. Sawazaki, S. Imai, M. Yokogawa, N. Hosoda, S. I. Hoshino, M. Mio, K. Mio, I. Shimada and M. Osawa, *Sci. Rep.*, 2018, **8**, 1455.
- D. A. Mangus, M. C. Evans and A. Jacobson, *Genome Biol.*, 2003, **4**, 223.
- Q. Vicens, J. S. Kieft and O. S. Rissland, *Mol. Cell*, 2018, **72**, 805–812.
- A. M. Borman, Y. M. Michel and K. M. Kean, *Nucleic Acids Res.*, 2000, **28**, 4068–4075.
- B. Kim, J. Seol, Y. K. Kim and J. B. Lee, *Exp. Mol. Med.*, 2023, **55**, 283–289.
- T. Preiss and M. W. Hentze, *Nature*, 1998, **392**, 516–520.
- H. Chen, D. Liu, J. Guo, A. Aditham, Y. Zhou, J. Tian, S. Luo, J. Ren, A. Hsu, J. Huang, F. Kostas, M. Wu, D. R. Liu and X. Wang, *Nat. Biotechnol.*, 2025, **43**, 194–203.
- L. K. McKenzie, R. El-Khoury, J. D. Thorpe, M. J. Damha and M. Hollenstein, *Chem. Soc. Rev.*, 2021, **50**, 5126–5164.
- M. Egli and M. Manoharan, *Nucleic Acids Res.*, 2023, **51**, 2529–2573.
- M. Takahashi, N. Minakawa and A. Matsuda, *Nucleic Acids Res.*, 2009, **37**, 1353–1362.
- O. Perzanowska, M. Smietanski, J. Jemielity and J. Kowalska, *Chemistry*, 2022, **28**, e202201115.
- H. Yi, J. Park, M. Ha, J. Lim, H. Chang and V. N. Kim, *Mol. Cell*, 2018, **70**, 1081–1088e1085.
- A. P. Petit, L. Wohlbold, P. Bawankar, E. Huntzinger, S. Schmidt, E. Izaurralde and O. Weichenrieder, *Nucleic Acids Res.*, 2012, **40**, 11058–11072.



- 24 M. Maryati, I. Kaur, G. P. Jadhav, L. Olotu-Umoren, B. Oveh, L. Hashmi, P. M. Fischer and G. S. Winkler, *Nucleic Acids Res.*, 2014, **42**, e30.
- 25 Y. Chen, E. Khazina, E. Izaurralde and O. Weichenrieder, *Nucleic Acids Res.*, 2021, **49**, 6489–6510.
- 26 B. Stupfler, C. Birck, B. Séraphin and F. Mauxion, *Nat. Commun.*, 2016, **7**, 10811.
- 27 A. Kahvejian, Y. V. Svitkin, R. Sukarieh, M. N. M'Boutchou and N. Sonenberg, *Genes Dev.*, 2005, **19**, 104–113.
- 28 J. Gao, Y. D. Tang, W. Hu and C. Zheng, *J. Virol.*, 2022, **96**, e0013622.
- 29 D. R. Gallie, *Translation*, 2014, **2**, e959378.
- 30 T. Sagae, M. Yokogawa, R. Sawazaki, Y. Ishii, N. Hosoda, S. I. Hoshino, S. Imai, I. Shimada and M. Osawa, *J. Biol. Chem.*, 2022, **298**, 101844.
- 31 A. H. Krotz, R. C. Mehta and G. E. Hardee, *J. Pharm. Sci.*, 2005, **94**, 341–352.
- 32 L. Wu, D. E. White, C. Ye, F. G. Vogt, G. J. Terfloth and H. Matsuhashi, *J. Mass Spectrom.*, 2012, **47**, 836–844.
- 33 H. Iwai, Y. Kimura, M. Honma, K. Nakamoto, K. Motosawa, T. Atago, K. Asano, F. Hashiya, N. Abe, K. Kobayashi, R. Ogisu, A. Hashimoto, K. Hiraishi, S. Saito, J. Yamamoto and H. Abe, *ChemRxiv*, 2024, preprint, DOI: [10.26434/chemrxiv-2024-bwpx6](https://doi.org/10.26434/chemrxiv-2024-bwpx6).
- 34 H. Yamada, H. Iwai, F. Hashiya, Y. Kimura, H. Abe and J. Yamamoto, *ChemBioChem*, 2025, **26**, e202400711.
- 35 N. L. Garneau, J. Wilusz and C. J. Wilusz, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 113–126.
- 36 J. Probst, S. Brechtel, B. Scheel, I. Hoerr, G. Jung, H. G. Rammensee and S. Pascolo, *Genet. Vaccines Ther.*, 2006, **4**, 4.
- 37 R. C. Deo, J. B. Bonanno, N. Sonenberg and S. K. Burley, *Cell*, 1999, **98**, 835–845.
- 38 M. Görlach, C. G. Burd and G. Dreyfuss, *Exp. Cell Res.*, 1994, **211**, 400–407.
- 39 F. Zeng and R. C. Harris, *Semin. Cell Dev. Biol.*, 2014, **28**, 2–11.
- 40 J. Berlanga-Acosta, J. Gavilondo-Cowley, P. López-Saura, T. González-López, M. D. Castro-Santana, E. López-Mola, G. Guillén-Nieto and L. Herrera-Martinez, *Int. Wound J.*, 2009, **6**, 331–346.
- 41 X. Tang, H. Liu, S. Yang, Z. Li, J. Zhong and R. Fang, *Mediators Inflammation*, 2016, **2016**, 1927348.
- 42 Y. S. Kim, D. H. Lew, K. C. Tark, D. K. Rah and J. P. Hong, *J. Korean Med. Sci.*, 2010, **25**, 589–596.
- 43 M. N. Tabrizi, C. Chams-Davatchi, N. Esmaeli, P. Noormohammadpoor, F. Safar, H. Etemadzadeh, H. A. Etehadhi and F. Gorouhi, *J. Eur. Acad. Dermatol. Venereol.*, 2007, **21**, 79–84.
- 44 K. Y. Chan, T. D. Lindquist, M. J. Edenfield, M. A. Nicolson and A. R. Banks, *Invest. Ophthalmol. Visual Sci.*, 1991, **32**, 3209–3215.
- 45 C.-H. Yang, Y.-B. Huang, P.-C. Wu and Y.-H. Tsai, *Process Biochem.*, 2005, **40**, 1661–1665.
- 46 N. Abe, A. Imaeda, M. Inagaki, Z. Li, D. Kawaguchi, K. Onda, Y. Nakashima, S. Uchida, F. Hashiya, Y. Kimura and H. Abe, *ACS Chem. Biol.*, 2022, **17**, 1308–1314.
- 47 D. D. Kang, H. Li and Y. Dong, *Adv. Drug Delivery Rev.*, 2023, **199**, 114961.
- 48 D. Kawaguchi, A. Kodama, N. Abe, K. Takebuchi, F. Hashiya, F. Tomoike, K. Nakamoto, Y. Kimura, Y. Shimizu and H. Abe, *Angew. Chem., Int. Ed.*, 2020, **59**, 17403–17407.
- 49 J. Hertler, K. Slama, B. Schober, Z. Özrendeci, V. Marchand, Y. Motorin and M. Helm, *Nucleic Acids Res.*, 2022, **50**, e115.
- 50 S. Abbasi, M. Matsui-Masai, F. Yasui, A. Hayashi, T. A. Tockary, Y. Mochida, S. Akinaga, M. Kohara, K. Kataoka and S. Uchida, *Mol. Ther.*, 2024, **32**, 1266–1283.
- 51 L. Carlsson, J. C. Clarke, C. Yen, F. Gregoire, T. Albery, M. Billger, A.-C. Egnell, L.-M. Gan, K. Jennbacken, E. Johansson, G. Linhardt, S. Martinsson, M. W. Sadiq, N. Witman, Q.-D. Wang, C.-H. Chen, Y.-P. Wang, S. Lin, B. Ticho, P. C. H. Hsieh, K. R. Chien and R. Fritsche-Danielson, *Mol. Ther. -Methods Clin. Dev.*, 2018, **9**, 330–346.

